Treatment resistant schizophrenia (TRS) is often encountered in clinical practice. Clozapine remains the drug of choice in the management of TRS. Several studies have shown that clozapine is the most effective antipsychotic medication to date for TRS. But it is also well known that it has multiple side effects. Some side effects are transient and relatively benign, while other adverse effects are menacing, serious and life-threatening. Delirium may occur with clozapine and is a therapeutic challenge as there is always a risk of precipitating delirium on clozapine rechallenge. Limited management strategies are available as alternatives for the management of psychiatric illness stabilized on clozapine. In this case report, we describe an older adult patient who developed delirium on clozapine. The aims of this case report are to discuss the mechanism by which clozapine leads to delirium, revisit various factors which could possibly lead to delirium, and discuss the different management strategies available for management of psychiatric illness for a patient previously stabilized on clozapine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0091217420972827 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 2016.
J Neural Transm (Vienna)
September 2024
Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, 30625, Hannover, Germany.
Article Synopsis
- Clozapine, a second-generation antipsychotic, shows better treatment outcomes for schizophrenia but comes with significant risks, as shown by a study on 38,349 inpatient patients from 1993-2016.
- The study found that 1.53% of patients experienced severe adverse drug reactions (ADRs), with older patients (≥65 years) at greater risk compared to younger ones (<65 years).
- Common severe ADRs included grand mal seizures, delirium, increased liver enzymes, and agranulocytosis, with five cases leading to death; the findings stress the need for careful monitoring and awareness of potential symptoms during clozapine treatment.
Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations - guideline "Parkinson's disease" of the German Society of Neurology.
J Neurol
December 2024
Movement Disorder Hospital, Beelitz-Heilstätten, Germany.
Article Synopsis
- Impulse control disorders, psychosis, and delirium are issues that can happen to people with Parkinson's disease, and new guidelines have been made to help doctors treat these conditions.
- Doctors should check patients on dopamine agonists for symptoms of impulse control disorders and adjust their medications as needed.
- The guidelines also suggest that doctors should use both medication and other therapies to help manage psychosis and delirium in Parkinson's patients.
Physostigmine reversal of delirium from second generation antipsychotic exposure: a retrospective cohort study from a regional poison center.
Clin Toxicol (Phila)
July 2024
MN Regional Poison Center, Minneapolis, Minnesota, USA.
Introduction: Physostigmine is an effective antidote for antimuscarinic delirium. There is little evidence for its use to reverse delirium following second generation antipsychotic exposure. The purpose of this study is to describe the safety and effectiveness of physostigmine in reversing delirium from second generation antipsychotic exposure.
View Article and Find Full Text PDFIvabradine-induced delirium in a patient taking clozapine for treatment-resistant schizophrenia: a case report.
East Asian Arch Psychiatry
March 2024
Department of Psychiatry, All India Institute of Medical Sciences, Deoghar, Jharkhand, India.
Antipsychotic medications and severe sepsis in schizophrenia: A nested case-control study.
Aust N Z J Psychiatry
October 2024
Department of General Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei.
Background: Sepsis constitutes a condition that involves life-threatening organ dysfunction induced by severe infection. This nested case-control study investigated risk factors for severe sepsis and whether antipsychotic use is associated with severe sepsis risk in patients with schizophrenia, a topic that has not been comprehensively explored in previous studies.
Methods: We selected 39,432 patients with schizophrenia aged between 15 and 65 years from Taiwan's Psychiatric Inpatient Medical Claims database for the period 2000-2012.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!